Zhongguo linchuang yanjiu (Dec 2023)

Immunotherapy for non-small cell lung cancer in special population

  • ZHAO Zhijuan,
  • XIONG Jie,
  • HE Guohua,
  • ZHAO Meng,
  • LIU Yu,
  • ZHAO Yuzhou,
  • REN Xiaoping

DOI
https://doi.org/10.13429/j.cnki.cjcr.2023.06.004
Journal volume & issue
Vol. 36, no. 6
pp. 816 – 820

Abstract

Read online

Lung cancer is a malignant disease with the highest mortality rate in the world, and it can be divided into small cell lung cancer and non-small cell lung cancer according to pathology. Non-small cell lung cancer is the most common. Most patients with lung cancer are diagnosed in an already advanced tumor stage when surgery is not an option for patients. However, traditional treatment has various shortcomings. With minimal adverse reactions and long-lasting effects, immunotherapy is another efficient treatment method in addition to chemotherapy and targeted therapy, and it has gradually become the first-line treatment for advanced non-small cell lung cancer. In view of the previous systematic reviews mainly on the general population, with limited attention to the special population, this article mainly summarizes the immunotherapy and focus in specific populations.

Keywords